Nuvalent
| Nuvalent
Company
Deck Type
Sector
Industry
Deck date
October 2023
Slide
15 of 52
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
a global first in human phase clinical trial of in advanced positive and other solid tumors dose preliminary data presented all treated population enrollment completed august updated data to be presented at medical meeting patient population harboring fusions by local testing prior for no limit to number prior chemotherapies or excluded concurrent drivers alk met ret or evaluable but non measurable disease allowed objectives enrollment initiated data as for patients treated by dose cohorts all doses dose expansion for dose optimization all treated population response evaluable population selection if applicable primary overall safety tolerability characterization preliminary activity intracranial activity central nervous system dose toxicities milligram maximum tolerated dose non small cell lung cancer once daily recommended with concurrent evaluation per protocol an patients drivers identified on plan tyrosine kinase testing patients without measurable disease are excluded from efficacy first response evaluation is pending patients response evaluable population prospect defined as all patients with measurable disease without concurrent driver who post response assessment treatment due progression death prior to the first response additional patients for no measurable tumor with alternate driver met amplification discontinued study treatment prior to first response assessment tumor pancreatic cancer source | Nuvalent
Investor Presentation
April 2024
a global first in human phase clinical trial of in advanced alk positive and other solid tumors dose preliminary data presented all treated population enrollment completed updated data to be presented at medical meeting enrollment initiated june data cut off dose cohorts all doses patient population dose harboring alk fusion or activating mutation by local testing patients with prior or alk for dose optimization prior chemotherapies all treated population excluded concurrent drivers met ret or evaluable but non measurable disease allowed response evaluable population objectives selection if applicable primary overall safety tolerability characterization preliminary activity intracranial activity non small cell with cor evaluation per i platinum base dor duration response maximum cancer objective rate overall survival on free survival dose tyrosine kinase drivers identified on subsequent testing patients without measurable disease are excluded from efficacy time to response inhibitor without prior to the first response for response no measurable disease at tumor with driver met amplification no post scan discontinued treatment for reasons than tumor pancreatic atypical carcinoid lung source lin | Nuvalent
Investor Presentation
February 2024
a global first in human phase clinical trial of in advanced positive and other solid tumors dose preliminary data presented all treated population enrollment completed august updated data to be presented at medical meeting patient population harboring fusions by local testing prior for no limit to number prior chemotherapies or excluded concurrent drivers alk met ret or evaluable but non measurable disease allowed objectives selection if applicable primary overall safety tolerability characterization preliminary activity intracranial activity enrollment initiated data as for patients treated by dose cohorts all doses dose expansion for dose optimization all treated population response evaluable population need i central nervous system dose limit once daily recommended patients with concurrent evaluation per toxicities milligram maximum tolerated tyrosine kinase identified on subsequent testing patients without measurable disease are excluded from efficacy ose non small cell lung cancer first response evaluation is pending response evaluable population prospectively defined as all patients with measurable disease without concurrent treatment due to progression death prior to the first tumor with altern driver met discontinued study treatment prior to first assessment tumor pancreatic cancer | Nuvalent
Investor Presentation
February 2024
a global first in human phase clinical trial of in advanced alk positive and other solid tumors dose preliminary data presented all treated population enrollment completed updated data to be presented at medical meeting enrollment initiated june data cut off dose cohorts all doses patient population dose harboring alk fusion or activating mutation by local testing patients with prior or alk for dose optimization prior chemotherapies all treated population excluded concurrent drivers met ret or evaluable but non measurable disease allowed response evaluable population objectives selection if applicable primary overall safety tolerability characterization preliminary activity intracranial activity on alk clinic non generation alk i rate i platinum base dor duration response maximum cancer objective survival progression free survival with cor evaluation per first response me to response evaluable population prospectively defined as all patients with at tumor scan discontinued treatment for reasons than tumor tic atypical carcinoid lung source lin | Nuvalent
Related slides by other companies
Nuvectis Pharma
Investor Presentation
August 2023
phase underway fast track designation | Nuvectis Pharma
Alkermes
Results
June 2021
artistry phase efficacy expansion initiated following determination of subcutaneous | Alkermes
Kymera
Investor Presentation
June 2023
phase dose and expansion trial to evaluate in adult patients with liquid and solid tumors | Kymera
Alkermes
Investor Day
March 2021
artistry phase efficacy expansion initiated following determination phase dose week lead in followed by combination of and either or cohorts a to a dose cohorts to dose phase efficacy expansion in solid tumors initiated at combination selected efficacy expansion in select solid tumors where previous responses were observed primary objectives safety and efficacy in combination with subcutaneous recommended phase dose administered once weekly administered once every three weeks secondary objectives include clinical profile and immunogenicity clinical pharmacodynamic effects all parts anti tumor activity phase and objective response rate and dor duration of response phase as fae | Alkermes
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io